Janus Henderson Investors

Founded 2017

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 58
Average round size
info
The average size of a deal this fund participated in
$107M
Portfolio companies 70
Rounds per year 14.50
Lead investments 5
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.07
Exits 38
Key employees 13

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Medical
  • Pharmaceutical
Summary

In 2017 was created Janus Henderson Investors, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the London. The company was established in Europe in United Kingdom.

For fund there is no match between the location of its establishment and the land of its numerous investments - United States. Among the various public portfolio startups of the fund, we may underline BioNtech, Sojournix, Bigfoot Biomedical Besides, a startup needs to be aged 4-5 years to get the investment from the fund. The fund has no exact preference in a number of founders of portfolio startups. Among the most successful fund investment fields, there are Machine Learning, Pharmaceutical.

We also calculated 11 valuable employees in our database.

Deals in the range of 50 - 100 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. The real fund results show that this Corporate Investor is 23 percentage points more often commits exit comparing to other companies.

The usual cause for the fund is to invest in rounds with 6-7 partakers. Despite the Janus Henderson Investors, startups are often financed by Versant Ventures, Sectoral Asset Management, Jeffrey Brewer. The meaningful sponsors for the fund in investment in the same round are Cormorant Asset Management, Redmile Group, RA Capital Management. In the next rounds fund is usually obtained by Visionnaire Ventures, Silicon Valley Bank, Senvest Capital.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Disc Medicine

Biotechnology
Health Care
Medical
$90M02 Sep 2021 Cambridge, Massachusetts, United States

Asher Bio

Biotechnology
Therapeutics
$108M01 Sep 2021 San Francisco, California, United States

CCC Information Services

Insurance
Service Industry
$150M02 Aug 2021 Chicago, Illinois, United States

Owlet Baby Care

Baby
Big Data
Consumer Electronics
Hardware
Health Care
Medical
Mobile
Software
$130M16 Jul 2021 Lehi, Utah, United States

Element Biosciences

Biotechnology
Information Technology
$276M29 Jun 2021 San Diego, California, United States

Synthekine

Biotechnology
Therapeutics
$107M10 Jun 2021 California, United States

NiKang Therapeutics

Biotechnology
Health Care
Medical
$200M26 May 2021 Wilmington, Delaware, United States

Magenta Therapeutics

Biotechnology
Medical
Therapeutics
$86M12 May 2021 Cambridge, Massachusetts, United States

TwinStrand Biosciences

Biotechnology
Genetics
Health Care
$50M06 May 2021 Seattle, Washington, United States
News
ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform

– ShouTi Inc. announced the close of a $100m Series B financing round.
– The round was led by BVF Partners. Additional new investors include Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Lilly Asia Ventures, Monashee Capital, Sage Partners, Stork Capital, Surveyor Capital (a Citadel company), TCG X, Terra Magnum Capital Partners, Woodline Partners, and co-founder and strategic partner Schrödinger.
– Existing investors also participated in the financing, including Eight Roads, F-Prime Capital Partners, Qiming Venture Partners, Sequoia Capital China, TF Capital and Wuxi AppTec.

Asher Bio Closes $108 Million Series B Financing

– Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, announced the closing of an oversubscribed Series B financing, which raised $108m.
– The financing was led by Wellington Management Company, and included new investors RA Capital Management, Janus Henderson Investors, Logos Capital, Marshall Wace and Alexandria Venture Investments, and, along with existing investors Third Rock Ventures, Invus, Boxer Capital of Tavistock Group, Mission BioCapital, and other undisclosed institutional investors.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Janus Henderson Investors?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: